Divided oral versus single-dose intravenous etoposide for hemophagocytic lymphohistiocytosis with comorbidity: lower early hematologic toxicity with preserved 2-week response

Etoposide is a backbone of hemophagocytic lymphohistiocytosis (HLH) treatment. But most adults suffering from HLH have comorbidity that limits the use of intravenous etoposide. We conducted a retrospective study to compare the efficacy and safety of divided oral versus single-dose intravenous etoposide within the DEP regimen (liposomal doxorubicin, etoposide, methylprednisolone) in HLH. We retrospectively analyzed a cohort of 57 patients (28 oral, 29 intravenous), including 13 patients under 18 years (six oral, seven intravenous). Week-2 overall response was the efficacy endpoint. The safety endpoint was any grade III–IV hematologic event at the worst grade recorded within 14 days after treatment. Patients with comorbidity were enrolled in both groups: 24/28 (85.7%) in the oral and 20/29 (69.0%) in the IV group. Week-2 overall response was 96.4% vs 89.7%, respectively. Grade III–IV hematologic events occurred in 5/28 (17.9%) oral and 16/29 (55.2%) IV group (p = 0.006). This association persisted after adjustment for lymphoma-associated HLH, age, performance status, comorbidity, LDH, AST, platelet and creatinine (odds ratios 0.13 to 0.19; all p ≤ 0.008). In the 44 patients with comorbidity, grade III–IV hematologic events were far less frequent (16.7% vs 65.0%; odds ratio 0.11; 95% confidence interval 0.03 to 0.44; p = 0.002). Compared to single-dose etoposide, divided oral dosing was associated with fewer grade III–IV hematologic events in comorbid HLH. However, if true absorption is much lower than 50% in critically ill patients, the apparent reduction in hematologic toxicity would in part reflect the lower dose administered rather than the route of administration. Further randomized pharmacokinetic studies are warranted. Oral etoposide within the DEP regimen was associated with fewer grade III–IV hematologic events in the first 14 days (17.9% vs 55.2%). The association persisted after adjustment for lymphoma-associated HLH, comorbidity, age, performance status and organ function.In the 44 patients with comorbidity, grade III–IV hematologic events were much less frequent with oral dosing (16.7% vs 65.0%), and the 2-week overall response rate was 95.8% vs 90.0%.If intravenous full-dose etoposide is unsafe, divided oral dosing is an alternative option to consider. Oral etoposide within the DEP regimen was associated with fewer grade III–IV hematologic events in the first 14 days (17.9% vs 55.2%). The association persisted after adjustment for lymphoma-associated HLH, comorbidity, age, performance status and organ function. In the 44 patients with comorbidity, grade III–IV hematologic events were much less frequent with oral dosing (16.7% vs 65.0%), and the 2-week overall response rate was 95.8% vs 90.0%. If intravenous full-dose etoposide is unsafe, divided oral dosing is an alternative option to consider.

Authors

Publication Details

Journal
Figshare
Published
2026-11-18
DOI
https://doi.org/10.6084/m9.figshare.35046613
Primary Topic
Autoimmune and Inflammatory Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Divided oral versus single-dose intravenous etoposide for hemophagocytic lymphohistiocytosis with comorbidity: lower early hematologic toxicity with preserved 2-week response

Leilei Chen, Gaochao Zhang, Jingshi Wang, Yubo Pi et al.
Figshare
Autoimmune and Inflammatory Disorders Research
article

Divided oral versus single-dose intravenous etoposide for hemophagocytic lymphohistiocytosis with comorbidity: lower early hematologic toxicity with preserved 2-week response

Leilei Chen, Gaochao Zhang, Jingshi Wang, Yubo Pi, Lin Wu, Zhao Wang
article en

Abstract

Etoposide is a backbone of hemophagocytic lymphohistiocytosis (HLH) treatment. But most adults suffering from HLH have comorbidity that limits the use of intravenous etoposide. We conducted a retrospective study to compare the efficacy and safety of divided oral versus single-dose intravenous etoposide within the DEP regimen (liposomal doxorubicin, etoposide, methylprednisolone) in HLH. We retrospectively analyzed a cohort of 57 patients (28 oral, 29 intravenous), including 13 patients under 18 years (six oral, seven intravenous). Week-2 overall response was the efficacy endpoint. The safety endpoint was any grade III–IV hematologic event at the worst grade recorded within 14 days after treatment. Patients with comorbidity were enrolled in both groups: 24/28 (85.7%) in the oral and 20/29 (69.0%) in the IV group. Week-2 overall response was 96.4% vs 89.7%, respectively. Grade III–IV hematologic events occurred in 5/28 (17.9%) oral and 16/29 (55.2%) IV group (p = 0.006). This association persisted after adjustment for lymphoma-associated HLH, age, performance status, comorbidity, LDH, AST, platelet and creatinine (odds ratios 0.13 to 0.19; all p ≤ 0.008). In the 44 patients with comorbidity, grade III–IV hematologic events were far less frequent (16.7% vs 65.0%; odds ratio 0.11; 95% confidence interval 0.03 to 0.44; p = 0.002). Compared to single-dose etoposide, divided oral dosing was associated with fewer grade III–IV hematologic events in comorbid HLH. However, if true absorption is much lower than 50% in critically ill patients, the apparent reduction in hematologic toxicity would in part reflect the lower dose administered rather than the route of administration. Further randomized pharmacokinetic studies are warranted. Oral etoposide within the DEP regimen was associated with fewer grade III–IV hematologic events in the first 14 days (17.9% vs 55.2%). The association persisted after adjustment for lymphoma-associated HLH, comorbidity, age, performance status and organ function.In the 44 patients with comorbidity, grade III–IV hematologic events were much less frequent with oral dosing (16.7% vs 65.0%), and the 2-week overall response rate was 95.8% vs 90.0%.If intravenous full-dose etoposide is unsafe, divided oral dosing is an alternative option to consider. Oral etoposide within the DEP regimen was associated with fewer grade III–IV hematologic events in the first 14 days (17.9% vs 55.2%). The association persisted after adjustment for lymphoma-associated HLH, comorbidity, age, performance status and organ function. In the 44 patients with comorbidity, grade III–IV hematologic events were much less frequent with oral dosing (16.7% vs 65.0%), and the 2-week overall response rate was 95.8% vs 90.0%. If intravenous full-dose etoposide is unsafe, divided oral dosing is an alternative option to consider.

Figshare
Good health and well-being
Autoimmune and Inflammatory Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon